Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/beta-catenin signaling
pubmed: wnt1 2024-04-25
Summary:
CONCLUSION: These results clearly reveal a novel potential of bufalin to suppress HCC through immunomodulation, and shed light on a new M2 macrophage-based modality of HCC immunotherapy, which additively enhances direct tumor-inhibitory efficacy of bufalin.